ABSTRACT OBJECTIVES This study sought to evaluate in-hospital outcomes and 3-year mortality of patients presenting with unprotected left main stem occlusion (ULMSO) treated with primary percutaneous coronary intervention (PPCI).
coronary intervention (PPCI) for acute MI, several small registries have investigated outcomes of patients undergoing emergency PPCI to left main stem (LMS) disease (2) .
However, only sporadic individual cases (3-7) and 5 small series (cumulatively n ¼ 112) (8) (9) (10) (11) (12) have reported outcomes of patients suffering from occlusive or subocclusive LMS disease (8) (9) (10) (11) (12) ) from which there is limited 1-year mortality data available (total n ¼ 100) (8, (10) (11) (12) .
These small studies, from several different populations, suggest that survival is poor (8) (9) (10) (11) (12) (13) (14) ; however, reliable contemporary information has not been collated previously, and this group has not been compared with outcomes from other emergency patients with MI. Given the paucity of data, management of this potentially catastrophic presentation poses a very significant challenge. We CLINICAL ENDPOINTS AND DEFINITIONS. We report the following: 1) demographic, clinical, and procedural characteristics of patients with ULMSO; 2) 3-year allcause mortality of the patients presenting with ULMSO stratified by the presence and absence of shock; 3) in-hospital rates of major adverse cardiac and cerebrovascular events (MACCE) defined as an accumulative composite of death, reinfarction or reintervention, in-hospital coronary artery bypass graft (CABG) and cerebrovascular events. Additionally, we aim to determine those factors that predict short-and long-term mortality.
STATISTICAL ANALYSIS. Normally distributed continuous variables (e.g., age and body mass index) are presented as mean AE SD and were analyzed using the independent samples Student t test. Skewed continuous variables (e.g., length of stay) are presented as median (interquartile range) and were analyzed using the Mann-Whitney U test. Categorical data are presented as counts and proportions of valid cases from the database, and statistical comparisons were made using the chi-square statistic. All-cause mortality rates are presented as counts and percentages and as mortality plots with the number of subjects known to be at risk at each successive time point. Group differences are assessed using the log-rank test. A 
Primary PCI of Unprotected LMS Occlusion S E P T E M B E R 2 0 1 4 : 9 6 9 -8 0 occlusive LMS disease; multivessel disease; intraaortic balloon pump support; glycoprotein (GP) IIb/ IIIa inhibitor use; thrombus aspiration use; and the presence of post-procedural no-reflow). Covariates with a p value of <0.05 at univariate analysis were entered into a final model using a forward stepwise method. Proportional hazards assumptions were evaluated and met for both outcomes and hazard ratios (HR) are presented as HR (95% confidence interval [CI]). All p values are 2-sided, and a p value of <0.05 was considered to be statistically significant.
All analyses were conducted in SPSS (version 20, SPSS, Inc., Chicago, Illinois). 
RESULTS

During the investigation period, in England and
IN-HOSPITAL CLINICAL OUTCOMES.
Of all patients having unprotected LMS PPCI, the in-hospital mortality was more than 6-fold higher than that of the non-LMS PPCI cohort (26.2% vs. 4.1%, respectively; p < 0.001) ( Table 3) . Patients with ULMSO had in-hospital MACCE (43.3% vs. 20.6%; p < 0.001) and mortality rates (41.6% vs. 19.3%; p < 0.001) that were approximately 2Â higher than those for patients with nonocclusive LMS disease. In all groups, the in-hospital MACCE rate was principally driven by in-hospital mortality ( Table 3 ). In the ULMSO group, 9 patients (1.6%) underwent urgent or emergency CABG, 7 patients suffered nonfatal MI or underwent reintervention, and a further 2 patients had embolic strokes. Additionally, 30.6% (174) of all ULSMO patients were treated in PCI centers without on-site surgical cover. This was associated with a slightly higher, but not statistically significant, increase in in-hospital mortality (46.2% vs.
39.6%; p ¼ 0.15).
CLINICAL FOLLOW-UP. The 1-year and 3-year allcause mortality rates for patients undergoing unprotected LMS PPCI were 39.8% and 60.4%, respectively, compared with 9.8% and 20.7%, respectively, in those having non-LMS PPCI (p < 0.001) ( Table 3 ). Mortality at both 1 and 3 years was adversely affected by the presence of periprocedural shock by approximately a factor of 2 in the unprotected LMS PPCI group (cardiogenic shock: 65.2% vs. no cardiogenic shock: 23.0%; p < 0.001 at 1 year; and cardiogenic shock: 80.7% vs. no cardiogenic shock: 43.5%; p < 0.001 at 3 years) and by a factor of >3 in the non-LMS PPCI group at 3 years (cardiogenic shock: 44.2% vs. no cardiogenic shock: 7.5%; p < 0.001 at 1 year; and cardiogenic shock: 61.4% vs. no cardiogenic shock: 17.4%; p < 0.001 at 3 years). The mortality plot in Figure 2A shows the mortality rate at 3-year follow-up for unprotected LMS PPCI and non-LMS PPCI groups stratified by the presence and absence of periprocedural cardiogenic shock and confirms a higher mortality in patients admitted with cardiogenic shock. Patel et al.
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Primary PCI of Unprotected LMS Occlusion 90.8%; p < 0.001) (Figure 3 ). In the absence of periprocedural cardiogenic shock, in this group, IABP use had a marginally lower mortality rate than for those in whom IABP was not used, but this difference was not statistically significant (53.1% vs. 48.8%;
The use of aspiration catheters in those with ULMSO was not associated with a mortality benefit at 3 years 8-12) . We report the first data from a comprehensive national registry of patients undergoing ULMSO PPCI. Our data documents that the incidence of presenting with ULMSO and undergoing PPCI is 0.6% of all PPCI (approximately 15 cases/year/100,000 population). Despite treatment, in-hospital mortality was 42%; 1-year mortality was 53%; and 3-year mortality was 74%.
The current medical literature of patients presenting with ULMSO is based on approximately 150
cases including those reported as single case reports (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , and outcomes from the largest series are summarized in Table 4 . These historical data can be contrasted with our presentation of contemporary and comprehensive U.K. interventional practice. In (26) and ACCF/AHA/SCAI guidelines (Class I and Class IIa recommendations, respectively) (27 -¼ data not available; other abbreviations as in Tables 1 to 3 .
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